Clinical Trial Update: Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update reporting safety, tolerability, immunogenicity, and antitumor activity of GEN-009 adjuvanted vaccine in melanoma and non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• GEN-009 adjuvanted vaccine

Snippet

Sponsor: Genocea Biosciences, Inc. | Conditions: Cutaneous Melanoma, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED